SLAM BioTherapeutics, a promising biotechnology company, dedicated to novel oncology and autoimmune therapies, announces a seed round of over $8 Million to advance its portfolio of antibodies. The company’s suite of antibodies targets a novel cell surface receptor expressed in the tumor microenvironment.

Leading the investment was Schwartz Capital Group. The funds raised will support SLAM Bio’s pre-clinical development efforts and facilitate Investigational New Drug (IND) enabling studies for its lead asset.

Yeda has been involved in the commercialization of scientific developments since 1959. "We have helped bring dozens of start-up companies and a variety of life-saving drugs to the world," says Dr. Opher Shapira, who heads the company and is responsible for the transition between a scientific idea and a business company

Yeda is excited to share more news originating from Curesponse, a commercial stage precision oncology company, which developed the cResponse™ platform, a functional-genomics oncology drug prioritization technology, that enables the precise determination of optimal drug treatments for individual cancer patients.

Curesponse is a spinoff company of Yeda.

This time Curesponse collaborated with Prof. Talia Golan, Head of the Pancreatic Cancer Center at Sheba medical hospital, which is ranked one of the top 10 hospitals in the world by Newsweek.

Yeda is thrilled to share news originating from Curesponse, which has developed a technology that enables the precise determination of optimal drug treatments for individual cancer patients.

This ground-breaking technology facilitates the analysis of samples extracted from cancerous tumors, providing oncologists with the means to assess the efficacy of different drugs on the patient's specific tumor.

Here’s what you missed from this exciting event last week on ECM Dynamics, organized by Prof. Irit Sagi at the Weizmann Institute of Science:

Experts convened to explore the vital role of ECM homeostasis and remodeling events in health and disease.

UltraSight and EchoNous Inc. have joined forces to enhance accessibility in cardiac ultrasound, empowering patients and healthcare providers alike. This partnership brings together Ultrasight's expertise in ultrasound solutions with Echonous' innovative technology, resulting in a breakthrough platform that improves patient experiences while maintaining diagnostic accuracy.

By making cardiac ultrasound more accessible and user-friendly, we aim to revolutionize the delivery of cardiac care.

Learn more about this transformative collaboration here:
 

In recent years, most early R&D for innovative biotech products has taken place in startups and small companies, while mature products are often commercialized by big pharma companies. Inspired by this trend, technology transfer companies have focused their efforts on spinning out companies to develop their technologies. The current economic uncertainty shines a spotlight on the challenges of bringing new technologies to market, and particularly academic spinouts requiring early-stage funding.

LightSolver, a spinoff company of Yeda - Technology Transfer Company of Weizmann Institute of Science, has been gaining well-deserved recognition as it works toward revolutionizing computing.

CEO & Co-Founder, Ruti Ben Shlomi, was recently featured in the acclaimed "Faces in Photonics" series by Laser Focus World.

In the feature, Ruti discusses the groundbreaking laser-based processing unit pioneered at LightSolver, developed in the lab of Nir Davidson at the Weizmann Institute of Science.

This represents a great vote of confidence in both Quantum Source and the broader field of quantum computing speaks to the growing interest and potential for innovation in this exciting area of technology.